Trials / Completed
CompletedNCT00990223
Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity
A Phase 1, Double-Blind (Sponsor Open), Randomized, Placebo-Controlled Trial To Evaluate The Effects Of 100 MG Once Daily Of Eplerenone On Serum Aldesterone And Plasma Renin Activity During 10 Days Of Dosing In Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the changes in serum aldosterone and plasma renin activity on Day 0 and on Days 1 and 10 after administration of 100 mg of eplerenone daily for 10 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eplerenone or Placebo | Eplerenone 100 mg or Placebo, daily for 10 days. |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2009-10-06
- Last updated
- 2020-12-22
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00990223. Inclusion in this directory is not an endorsement.